Fudan University: Carcinoma, Hepatocellular trials

The registry lists 46 Carcinoma, Hepatocellular studies with Fudan University as lead sponsor. 18 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 5Phase 2 22Phase 3 8Phase 4 2No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCCNot yet recruitingNCT07412054Phase 2
• TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan CriteriaRecruitingNCT07268131Not applicable
• The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver TumorsRecruitingNCT07159048Not applicable
• TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune MicroenvironmentRecruitingNCT07100405
• Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and BevacizumabRecruitingNCT07100392Phase 2
• Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and BevacizumabRecruitingNCT07047586Phase 2
• TACE Plus Ivonescimab for Unresectable Non-Metastatic HCCNot yet recruitingNCT06990620Phase 1
• HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)RecruitingNCT06860490Phase 2
• HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of RecurrenceRecruitingNCT06812039Phase 2
• HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular CarcinomaNot yet recruitingNCT06475287Phase 2
• Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular CarcinomaNot yet recruitingNCT06441019Phase 2
• Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT06285019Phase 2
• Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)RecruitingNCT05897268Phase 2
• Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver MetastasesRecruitingNCT05771025Not applicable
• Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT05675462Phase 1
• A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver CancerNot yet recruitingNCT05660213
• Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular CarcinomaRecruitingNCT05057845Phase 2
• The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)Not yet recruitingNCT04517227Not applicable
• Efficacy and Safety of T+A+RAD in HCCStatus unknownNCT05396937Phase 2
• HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After ResectionStatus unknownNCT05311319Phase 2
• Tislelizumab in the Systematic Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT04996459
• PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCCStatus unknownNCT04974281Early Phase 1
• TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02)CompletedNCT04954794Phase 2
• Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCCStatus unknownNCT04843943Phase 1/2
• cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven CriteriaCompletedNCT04842565Phase 2
• TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular CarcinomaCompletedNCT04297280Phase 2
• Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular CarcinomaStatus unknownNCT03838796Not applicable
• Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACEStatus unknownNCT03642561Phase 2/3
• TACE Combined With RFA/MV Treatment in Hepatocellular Carcinoma Beyond Milan CriterialCompletedNCT03636620Phase 3
• Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular CarcinomaTerminatedNCT02748304Not applicable
• Efficacy Study of TACE to Treat Hepatocellular Carcinoma After OperationStatus unknownNCT02631499Phase 4
• Laparoscopic Versus Open Liver Resection for Hepatocellular CarcinomaStatus unknownNCT02526043Not applicable
• Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical SurgeryStatus unknownNCT01936233Phase 3
• Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPaseStatus unknownNCT01715532Phase 2
• Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 ExpressionStatus unknownNCT01681446Phase 3
• Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCCStatus unknownNCT01259193Phase 2
• Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) TherapyStatus unknownNCT01102335Phase 4
• Efficacy of Postoperative Adjuvant Treatments for Hepatocellular Carcinoma With Portal Vein Tumor ThrombosisStatus unknownNCT01033578Not applicable
• Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver CancerStatus unknownNCT00999843Phase 1/2
• Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular CarcinomaStatus unknownNCT00921531Phase 3
• Radiation Dose Escalation Study for Advanced Liver CancerCompletedNCT00848094Phase 1
• The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular CarcinomaWithdrawnNCT00838968Not applicable
• Songyou Granule and Transarterial Chemoembolization for Hepatocellular CarcinomaStatus unknownNCT00805896Phase 2
• Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative ResectionStatus unknownNCT00561522Phase 2/3
• Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan CriteriaStatus unknownNCT00554125Phase 3
• Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular CarcinomaStatus unknownNCT00460681Phase 3